184 426

Cited 0 times in

Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18 F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors

DC Field Value Language
dc.contributor.author김소영-
dc.contributor.author왕지영-
dc.contributor.author정민규-
dc.contributor.author정용휴-
dc.contributor.author조응혁-
dc.contributor.author황상현-
dc.date.accessioned2021-05-26T16:47:10Z-
dc.date.available2021-05-26T16:47:10Z-
dc.date.issued2021-01-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182837-
dc.description.abstractBackground: This study aimed to evaluate the prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with localized primary gastrointestinal stromal tumors (GISTs) and to compare the predictive values of 18F-FDG PET/CT parameters with those of clinicopathological prognostic factors. Methods: Sixty-two localized GIST patients who underwent staging with 18F-FDG PET/CT from January 2007 to December 2013 before surgery were retrospectively enrolled. A volume of interest with a standardized uptake value (SUV) threshold of 2.5 was used to determine the metabolic tumor volume (MTV) and total lesion glycolysis (TLG). These metabolic indices, along with the maximum SUV (SUVmax), were analyzed to evaluate recurrence-free survival (RFS). Other significant clinical and pathologic indices were also retrospectively reviewed for RFS analysis. Results: Patients were followed up for a median of 42.0 months (range, 5.6-111.5). During the follow-up period, 13 patients (21.0%) experienced disease recurrence. In univariate analysis, tumor size (> 5 cm), mitotic count (> 5/high-power field), modified National Institutes of Health (NIH) consensus criteria, adjuvant imatinib treatment, SUVmax (≥ 7.04), MTV (≥ 50.76 cm3), and TLG (≥ 228.79 g) were significant prognostic factors affecting RFS (p < 0.05). In multivariate analysis, only MTV (hazard ratio, 17.69; 95% confidence interval [CI], 2.03-154.17, p = 0.009) and TLG (hazard ratio, 20.48; 95% CI, 2.19-191.16, p = 0.008) were independent prognostic factors for RFS. The 5-year RFS rates were 96.4% and 96.6% in patients with a low MTV and TLG and 27.3% and 23.6% in patients with a high MTV and TLG, respectively (p < 0.001). Conclusion: MTV and TLG are independent prognostic factors for predicting recurrence in patients with localized primary GIST. Patients with a high MTV or TLG are at risk for poor prognosis and should be closely observed for disease recurrence.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBioMed Central-
dc.relation.isPartOfCANCER & METABOLISM-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePrognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18 F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Nuclear Medicine (핵의학교실)-
dc.contributor.googleauthorSang Hyun Hwang-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorYong Hyu Jeong-
dc.contributor.googleauthorKwanHyeong Jo-
dc.contributor.googleauthorSoyoung Kim-
dc.contributor.googleauthorJiyoung Wang-
dc.contributor.googleauthorArthur Cho-
dc.identifier.doi10.1186/s40170-021-00244-x-
dc.contributor.localIdA05460-
dc.contributor.localIdA05697-
dc.contributor.localIdA03606-
dc.contributor.localIdA05554-
dc.contributor.localIdA03887-
dc.contributor.localIdA05953-
dc.relation.journalcodeJ04025-
dc.identifier.eissn2049-3002-
dc.identifier.pmid33509304-
dc.subject.keyword18F-Fluorodeoxyglucose-
dc.subject.keywordGastrointestinal stromal tumor-
dc.subject.keywordMetabolic tumor volume-
dc.subject.keywordPET-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNameKim, Soyoung-
dc.contributor.affiliatedAuthor김소영-
dc.contributor.affiliatedAuthor왕지영-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor정용휴-
dc.contributor.affiliatedAuthor조응혁-
dc.contributor.affiliatedAuthor황상현-
dc.citation.volume9-
dc.citation.number1-
dc.citation.startPage8-
dc.identifier.bibliographicCitationCANCER & METABOLISM, Vol.9(1) : 8, 2021-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.